FDA Approves First Oral Treatment for Adult Dermatomyositis

The U.S. FDA has approved Lisraya (brepocitinib) tablets, the first oral treatment option for adults with dermatomyositis. This rare autoimmune disease causes chronic inflammation, muscle weakness, and skin rashes. The approval addresses a significant unmet medical need, providing an effective alternative to previously limited treatment options for patients.